- Leading Innovation and Data Security as a Global Medical AI Company
- To Participate in European Congress of Radiology and Australian Lung Cancer Conference in February
Medical AI company Coreline Soft, led by CEO Jin-Guk Kim, announced on 24 January that it has simultaneously obtained compliance certifications with Europe's General Data Protection Regulation (GDPR) and the U.S. Health Insurance Portability and Accountability Act (HIPAA), considered the highest authorities in global medical data protection.
This achievement demonstrates Coreline Soft's adherence to the highest standards for medical data safety and personal data protection, enhancing its trustworthiness and competitiveness in the global medical AI market.
The GDPR is the European Union's data protection regulation aimed at preventing unauthorized use of user information through stringent data protection standards. Meanwhile, HIPAA is the U.S. law focused on ensuring the confidentiality and security of medical information. These certifications are essential conditions for entering the European and U.S. markets, validated through rigorous assessments by certification bodies. This confirms the global-standard technology and data management capabilities of Coreline Soft.
Coreline Soft has successfully conducted lung cancer screening projects in several countries, including Germany (HANSE) and Italy (RISP), securing unique competitiveness. As leading European nations like Germany recommend mandatory AI in lung cancer screening pilot projects, the company is intensively marketing for similar projects underway in various countries.
In the U.S., the largest healthcare market, Coreline Soft is expanding smoothly. Last year, it sold the simultaneous chest disease diagnostic product AVIEW LCS Plus, which detects early lung cancer, emphysema, and coronary artery calcium (CAC), to UMass Memorial Medical Center, a top 5 hospital in Massachusetts. Also, by the end of the year, it sold three major products to Temple Lung Center under Temple University Hospital, the leader in respiratory disease care.
With these certifications, Coreline Soft plans to guarantee reliability and stability in all medical data processes and strengthen its position in the expanding global lung cancer screening market.
Hye-Yi Park, Director of Regulatory Innovation at Coreline Soft, stated, "These certifications further recognize Coreline Soft's reliability and technological prowess in the global market, including Europe and the U.S. We will continue to prioritize data security and quality, contributing to the innovation and spread of medical AI solutions."
In February, Coreline Soft will participate in numerous global conferences in Europe and North America. It plans to showcase strategic consulting and product-specific promotions based on the AVIEW LCS product, which significantly enhances the efficiency and accuracy of lung cancer screening. Major events include the Global AI Conference in London, UK, and the Radiology Review Course in Ottawa, Canada. The company will also demonstrate its products and share its AI interpretation effects at the Australian Lung Cancer Conference (ALCC) 2025.
